Crossmark

GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia

Crossref DOI link: https://doi.org/10.1007/s40121-022-00596-x

Published Online: 2022-02-03

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

De Ryck, Iris https://orcid.org/0000-0003-3044-1117
Sarakinou, Eleanna

Nakakana, Usman

Cilio, Giulia Luna

Ndiaye, Augustin

Vella, Venanzio

Auerbach, Joachim

Granada, Juan-Paolo

Conti, Valentino

Podda, Audino
Funding

Funding for this research was provided by:

GlaxoSmithKline Biologicals SA
License Information

Text and Data Mining valid from 2022-02-03

Version of Record valid from 2022-02-03
More Information

Article History

Received: 26 November 2021

Accepted: 21 January 2022

First Online: 3 February 2022

Change Date: 18 April 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40121-022-00634-8

Updates are available Correction dated 2022-04-18

Click to view Correction: https://doi.org/10.1007/s40121-022-00634-8